Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Voting Common Stock, par value $0.0001 per share
-
Shares outstanding
-
5,381,598
-
Total 13F shares
-
3,295,608
-
Share change
-
+1,677,509
-
Total reported value
-
$27,078,858
-
Price per share
-
$8.25
-
Number of holders
-
35
-
Value change
-
+$7,676,587
-
Number of buys
-
20
-
Number of sells
-
17
Institutional Holders of Aligos Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (ALGS) as of Q1 2025
As of 31 Mar 2025,
Aligos Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (ALGS) was held by
35 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,295,608 shares.
The largest 10 holders included
ADAGE CAPITAL PARTNERS GP, L.L.C., Deep Track Capital, LP, Alyeska Investment Group, L.P., Woodline Partners LP, Hudson Bay Capital Management LP, HEIGHTS CAPITAL MANAGEMENT, INC, Sio Capital Management, LLC, BANK OF AMERICA CORP /DE/, TANG CAPITAL MANAGEMENT LLC, and VANGUARD GROUP INC.
This page lists
35
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.